SNPHY News and Press, Santen Pharmaceutical Co. Ltd. ADR

2024-05-17 12:52:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Santen Pharmaceutical (OTCMKTS: SNPHY ) just reported results for the fourth quarter of 2023. Santen Pharmaceutical reported earnings per share of 16 cents. The compan...

2024-02-08 12:44:29 ET More on Santen Pharmaceutical Historical earnings data for Santen Pharmaceutical Co Dividend scorecard for Santen Pharmaceutical Co Financial information for Santen Pharmaceutical Co Read the full article on Seeking Alpha For fu...

2023-11-07 11:11:37 ET More on Santen Pharmaceutical Co., Ltd. Historical earnings data for Santen Pharmaceutical Co., Ltd. Financial information for Santen Pharmaceutical Co., Ltd. For further details see: Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥69.68,...

2023-08-04 08:55:08 ET Santen Pharmaceutical Co., Ltd. press release ( OTCPK:SNPHY ): Q1 Net profit of ¥10.4B Revenue of ¥72.4B. For further details see: Santen Pharmaceutical Co., Ltd. reports Q1 results

2023-05-11 12:32:48 ET Santen Pharmaceutical Co. press release ( OTCPK:SNPHY ): FY core net profit of ¥33.2B. Revenue of ¥279B (+4.8% Y/Y). FY23 revenue expected to be ¥273.0B and core net profit of ¥34.5B. For further details see: Santen Phar...

Santen Pharmaceutical Co., Ltd. press release ( OTCPK:SNPHY ): Q3 GAAP EPS of ¥54.11. Revenue of ¥199.8B (+2.0% Y/Y). For further details see: Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥54.11, revenue of ¥199.8B

Santen Pharmaceutical's ( OTCPK:SNPHY ) ( OTCPK:SNPHF ) unit Santen Canada received Health Canada's approval of Cationorm Plus for relief of dry eye and ocular allergy symptoms. Cationorm Plus is a sterile, preservative-free, artificial tear containing a...

Santen Pharmaceutical Co., Ltd. (SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 03:30 ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Presentation Peter Sallstig [Foreign Language] Thank ...

The following slide deck was published by Santen Pharmaceutical Co., Ltd. in conjunction with their 2022 Q3 earnings call. For further details see: Santen Pharmaceutical Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation

Aerie Pharmaceuticals (NASDAQ:AERI) and Santen (OTC:SNPHF) have entered into an exclusive development and commercialization agreement for Rhopressa/Rhokiinsa (netarsudil ophthalmic solution) 0.02% and Rocklatan/Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expand...